H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Ocugen to $7 from $5 and keeps a Buy rating on the shares. The analyst says OCU400 will enter a late-stage study in 2024. The firm expects initial readout from the pivotal study in early 2025 and projects risk-adjusted revenues of $458M by the end of 2030.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCGN:
- Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
- Ocugen appoints Bob Smith to business advisory board
- Biotech Alert: Searches spiking for these stocks today
- Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
- Ocugen gains FDA alignment on key aspects of OCU400 Phase 3 trial
